DPP-4抑制剂西格列汀治疗新诊断老年2型糖尿病的疗效及其对血压、体质量的影响研究  

DPP-4 inhibitor Sig Leo Dean on the newly diagnosed type 2 diabetes mellitus and its effect on blood pressure and body weight

作　　者：蔡奕琪[1] 吕全[2] 王盈盈[1] 阮希成[1] 金希波[1] Cai Yiqi Lv Quan Wang Yingying Ruan Xicheng Jin Xibo(Department of Endocrine Department of Ophthalmology ,Mindong Hospital Affiliated to Fujian Medical University, Fuan, Fujian 355000, China)

机构地区：[1]福建医科大学附属闽东医院内分泌科,福建福安355000 [2]福建医科大学附属闽东医院眼科,福建福安355000

出　　处：《重庆医学》2017年第11期1476-1477,1481,共3页Chongqing medicine

基　　金：宁德市科学技术计划项目(20130144)

摘　　要：目的探讨DPP-4抑制剂西格列汀治疗新诊断老年2型糖尿病的临床疗效及其对血压、体质量的影响。方法选取该院2013年7月至2015年6月收治的100例新诊断老年2型糖尿病患者作为研究对象,将其分为观察组和对照组,每组50例。对照组在饮食控制及锻炼的基础上使用安慰剂进行治疗,观察组在饮食控制及锻炼基础上使用西格列汀进行治疗。对比患者治疗前后的空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化清蛋白(GA)的变化情况,监测低血糖发生率、血压、体质量等变化及不良反应。结果治疗后,两组患者的病情均明显好转,且观察组FPG、2hPG、GA的变化情况均显著优于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者血压、体质量和BMI与治疗前比较差异均无统计学意义(P>0.05)。治疗后,观察组与对照组不良反应发生率分别为10.0%和8.0%,差异无统计学意义(P>0.05)。结论应用DPP-4抑制剂西格列汀治疗新诊断老年2型糖尿病患者临床疗效好。Objective To investigate the clinical efficacy of DPP-4 inhibitors in the treatment of newly diagnosed type 2 dia- betes mellitus and its effect on blood pressure and body weight. Methods A total of 100 newly diagnosed elderly patients with type 2 diabetes mellitus were enrolled in this study from July 2013 to June 2015 in this hospital. They were divided into observation group and control group（n= 50）. The control group was treated with placebo on the basis of diet control and e：tercise. The observa- tion group was treated with sitagliptin on the basis of diet control and exercise. Fasting plasma glucose（FPG）, 2 h postprandial blood glucose（2 h PG） and glycated albumin （GA） were measured before and after treatment,and the incidence rate of hypoglyce- mia, blood pressure, body weight and other adverse reactions were monitored. Results After treatment, two groups of patients, con- dition were significantly improved,FPG, 2 h PG, GA changes in observation group were significantly better than that of control group,the difference were statistically significant（P〈0.05）. There was no significant difference in blood pressure, body weight and body mass index before and after treatment,and also between the two groups（P〉0.05）. The incidence of adverse reactions in the observation group and the control group were 10.0% and 8.0% ,The incidence of adverse reactions in the two groups was not sta- tistically significant（P〉0.05）. Conclusion The clinical efficacy of DPP-4 inhibitor siglitazide in the treatment of newly diagnosed elderly patients with type 2 diabetes mellitus is good,and it is very useful in the treatment of these patients.

关 键 词：DPP-4抑制剂 西格列汀 新诊断 糖尿病 2型 血压 体重 老年人 

分 类 号：R587.1[医药卫生—内分泌]